secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2021-08-25T23:59:59+00:00
Accession:  0000950170-21-001559
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences appoints Nancy Whiting to board of directors
----------------------------------------------------------------

- Nancy Whiting, Pharm.D., appointed as Class II director effective August 24, 2021.
- She receives $40,000 annual cash retainer plus $5,000 for compensation committee service.
- Dr. Whiting brings over 17 years of biotech experience, most recently as EVP at Seagen Inc.
- Her oncology drug development expertise aligns with Caribou's pipeline of allogeneic cell therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000095017021001559/0000950170-21-001559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000095017021001559/crbu-20210824.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-001559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer